| P2093 | author name string | T Fehm | |
| | E F Solomayer | |
| | I Juhasz-Boess | |
| | J T Ney | |
| P2860 | cites work | Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation | Q24311588 |
| | Osteoprotegerin: a novel secreted protein involved in the regulation of bone density | Q24313918 |
| | Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis | Q24324701 |
| | A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function | Q24336057 |
| | RANK is essential for osteoclast and lymph node development | Q24598872 |
| | osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification | Q24603266 |
| | Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand | Q24653311 |
| | Evidence for a role of a tumor necrosis factor-alpha (TNF-alpha)-converting enzyme-like protease in shedding of TRANCE, a TNF family member involved in osteoclastogenesis and dendritic cell survival | Q28142897 |
| | The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma | Q28236113 |
| | Denosumab in postmenopausal women with low bone mineral density | Q28298728 |
| | OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis | Q28589430 |
| | Receptor activator of NF-kB (RANK) expression in primary tumors associates with bone metastasis occurrence in breast cancer patients | Q28740575 |
| | Metastasis to bone: causes, consequences and therapeutic opportunities | Q29614310 |
| | Genetic regulation of osteoclast development and function | Q29617421 |
| | Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand | Q29619331 |
| | Transforming Growth Factor-Beta in Osteolytic Breast Cancer Bone Metastases | Q30311918 |
| | Hypercalcaemia of malignancy and basic research on mechanisms responsible for osteolytic and osteoblastic metastasis to bone | Q30438085 |
| | Tumor-derived interleukin-8 stimulates osteolysis independent of the receptor activator of nuclear factor-kappaB ligand pathway | Q33228319 |
| | Cellular and molecular mechanisms of bone remodeling. | Q34055657 |
| | Characterization of structural domains of human osteoclastogenesis inhibitory factor | Q34457751 |
| | Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. | Q34469691 |
| | Expression of osteoprotegerin (OPG), TNF related apoptosis inducing ligand (TRAIL), and receptor activator of nuclear factor kappaB ligand (RANKL) in human breast tumours | Q35769514 |
| | Expression of receptor activator of nuclear factor kappabeta ligand (RANKL) and tumour necrosis factor related, apoptosis inducing ligand (TRAIL) in breast cancer, and their relations with osteoprotegerin, oestrogen receptor, and clinicopathological | Q35770122 |
| | Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength | Q36269835 |
| | TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts. | Q36404187 |
| | Advances in the biology of bone metastasis: how the skeleton affects tumor behavior | Q37774077 |
| | Examination of the mechanisms of osteolysis in patients with metastatic breast cancer. | Q38422014 |
| | Immunological characterization of circulating osteoprotegerin/osteoclastogenesis inhibitory factor: increased serum concentrations in postmenopausal women with osteoporosis | Q39118073 |
| | Transgenic mice overexpressing soluble osteoclast differentiation factor (sODF) exhibit severe osteoporosis | Q39124107 |
| | Bone metastases detection by circulating biomarkers: OPG and RANK-L. | Q39558983 |
| | Soluble TRAIL could enhance bone destruction acting on Rank-ligand in estrogen-independent human breast cancer cell line MDA-MB-231. | Q39908493 |
| | Osteolysis and cancer | Q39946675 |
| | Expression of osteoprotegerin and receptor activator of nuclear factor-kappaB ligand (RANKL) in HCC70 breast cancer cells and effects of treatment with gonadotropin-releasing hormone on RANKL expression | Q39967650 |
| | Breast adenocarcinoma MCF-7 cell line induces spontaneous osteoclastogenesis via a RANK-ligand-dependent pathway. | Q39992744 |
| | Investigating the interaction between osteoprotegerin and receptor activator of NF-kappaB or tumor necrosis factor-related apoptosis-inducing ligand: evidence for a pivotal role for osteoprotegerin in regulating two distinct pathways | Q40093202 |
| | Regulation of cancer cell migration and bone metastasis by RANKL. | Q40298349 |
| | Osteoprotegerin (OPG) expression by breast cancer cells in vitro and breast tumours in vivo--a role in tumour cell survival? | Q40374890 |
| | The expression of osteoprotegerin and RANK ligand and the support of osteoclast formation by stromal-osteoblast lineage cells is developmentally regulated | Q40838648 |
| | Osteoprotegerin and osteoprotegerin ligand effects on osteoclast formation from human peripheral blood mononuclear cell precursors | Q41607334 |
| | Expression of osteoprotegerin and RANK ligand in breast cancer bone metastasis | Q42032211 |
| | Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study | Q42829926 |
| | Tumour cells produce receptor activator of NF-kappaB ligand (RANKL) in skeletal metastases | Q43011355 |
| | Markers of bone remodeling and skeletal morbidity in patients with solid tumors metastatic to the skeleton receiving the biphosphonate zoledronic acid | Q43093358 |
| | The effect of a single dose of osteoprotegerin in postmenopausal women | Q43520860 |
| | Bone metastases in breast cancer: higher prevalence of osteosclerotic lesions | Q43827958 |
| | A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases | Q44291815 |
| | Osteoprotegerin and osteopontin serum values in postmenopausal advanced breast cancer patients treated with anastrozole | Q45197443 |
| | Expression pattern of receptor activator of NFκB (RANK) in a series of primary solid tumors and related bone metastases | Q45814967 |
| | Effect of denosumab on bone mineral density in women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: subgroup analyses of a phase 3 study | Q46077710 |
| | Extended efficacy and safety of denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapy | Q46312540 |
| | Continuous RANKL inhibition in osteoprotegerin transgenic mice and rats suppresses bone resorption without impairing lymphorganogenesis or functional immune responses | Q46891798 |
| | A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer | Q46952812 |
| | A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. 2004. | Q48607259 |
| | Soluble RANKL induces high bone turnover and decreases bone volume, density, and strength in mice. | Q51703171 |
| | Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. | Q51803777 |
| | Functional dissection of osteoprotegerin and its interaction with receptor activator of NF-kappaB ligand. | Q52661548 |
| | Osteoprotegerin ligand regulates osteoclast adherence to the bone surface in mouse calvaria. | Q54043106 |
| | Melanoma cells stimulate osteoclastogenesis, c-Src expression and osteoblast cytokines | Q57008067 |
| | Effects of denosumab on bone mineral density and bone turnover in patients with rheumatoid arthritis receiving concurrent glucocorticoids or bisphosphonates | Q57752076 |
| | Abnormal bone remodeling process is due to an imbalance in the receptor activator of nuclear factor–κB ligand (RANKL)/osteoprotegerin (OPG) axis in patients with solid tumors metastatic to the skeleton | Q57904787 |
| | Effects of denosumab on bone turnover markers in postmenopausal osteoporosis | Q58970691 |
| | Randomized Active-Controlled Phase II Study of Denosumab Efficacy and Safety in Patients With Breast Cancer-Related Bone Metastases | Q62392239 |
| | Histomorphometric analysis of sclerotic bone metastases from prostatic carcinoma special reference to osteomalacia | Q71227747 |
| | Breast cancer cells interact with osteoblasts to support osteoclast formation | Q73025244 |
| | Serum osteoprotegerin levels in healthy controls and cancer patients | Q74453219 |
| | Differential gene expression of TGF-beta family members and osteopontin in breast tumor tissue: analysis by real-time quantitative PCR | Q74701407 |
| | Measurement of bone morphogenetic proteins and other growth factors in demineralized bone matrix | Q75418573 |
| | Expression of receptor activator of nuclear factor-kappaB is inversely correlated with metastatic phenotype in breast carcinoma | Q81321200 |
| | The relative use of eight collagenous and noncollagenous markers for diagnosis of skeletal metastases in breast, prostate, or lung cancer patients | Q82361812 |
| | Denosumab-mediated increase in hand bone mineral density associated with decreased progression of bone erosion in rheumatoid arthritis patients | Q84062765 |
| P433 | issue | 5 | |
| P304 | page(s) | 385-391 | |
| P577 | publication date | 2012-05-01 | |
| P1433 | published in | Geburtshilfe und Frauenheilkunde: Ergebnisse der Forschung für die Praxis | Q26841999 |
| P1476 | title | RANK, RANKL and OPG Expression in Breast Cancer - Influence on Osseous Metastasis | |
| P478 | volume | 72 | |